APOE and Alzheimer disease: Although clinical trials of the Aβ-directed mAbBapinezumab showed no clear cognitive benefits in patients with mild tomoderate AD [42], the resultsalso indicated that APOE ε4 carrier status may limit the response to anti-Aβpassive immunization [43,44], aswell as being associated with an increased rate of microbleeds and vasogenicedema [45].